APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oral Mesalazine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oral Mesalazine Market Outlook and Growth Opportunities 2026

Report ID 174019990422 December 2025198 pages

Choose your research edition.

Industry ResearchOral Mesalazine Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Mesalazine Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Oral Mesalazine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Mesalazine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Mesalazine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Oral Mesalazine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oral Mesalazine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Mesalazine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Mesalazine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oral Mesalazine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oral Mesalazine market include Teva Pharmaceutical Industries, Ferring Global, AbbVie, Tillotts Pharma, Shire, Salix Pharmaceuticals, Nogra Pharma Limited, Morningside Healthcare and Dr. Falk Pharma UK, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Oral Mesalazine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Mesalazine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Mesalazine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oral Mesalazine market.

Oral Mesalazine Segment by Company

Teva Pharmaceutical Industries

Ferring Global

AbbVie

Tillotts Pharma

Shire

Salix Pharmaceuticals

Nogra Pharma Limited

Morningside Healthcare

Dr. Falk Pharma UK

Oral Mesalazine Segment by Type

Capsules

Granule

Tablets

Oral Mesalazine Segment by Application

Inflammatory Bowel Disease

Ulcerative Colitis

Crohn's Disease

Others

Oral Mesalazine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oral Mesalazine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oral Mesalazine key companies, revenue, market share, and recent developments.

3. To split the Oral Mesalazine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oral Mesalazine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oral Mesalazine significant trends, drivers, influence factors in global and regions.

6. To analyze Oral Mesalazine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Mesalazine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Mesalazine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Mesalazine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Mesalazine industry.

Chapter 3: Detailed analysis of Oral Mesalazine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oral Mesalazine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oral Mesalazine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oral Mesalazine Industry Trends Table 2. Oral Mesalazine Industry Drivers Table 3. Oral Mesalazine Industry Opportunities and Challenges Table 4. Oral Mesalazine Industry Restraints Table 5. Global Oral Mesalazine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oral Mesalazine Revenue Share by Company (2021-2026) Table 7. Global Oral Mesalazine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oral Mesalazine Key Company Manufacturing Base & Headquarters Table 9. Global Oral Mesalazine Company, Product Type & Application Table 10. Global Oral Mesalazine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oral Mesalazine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Capsules Table 15. Significant Companies of Granule Table 16. Significant Companies of Tablets Table 17. Global Oral Mesalazine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Oral Mesalazine Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Oral Mesalazine Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Oral Mesalazine Sales Value Share by Type (2021-2026) Table 21. Global Oral Mesalazine Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Inflammatory Bowel Disease Table 23. Significant Companies of Ulcerative Colitis Table 24. Significant Companies of Crohn's Disease Table 25. Significant Companies of Others Table 26. Global Oral Mesalazine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Oral Mesalazine Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Oral Mesalazine Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Oral Mesalazine Sales Value Share by Application (2021-2026) Table 30. Global Oral Mesalazine Sales Value Share by Application (2027-2032) Table 31. Global Oral Mesalazine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Oral Mesalazine Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Oral Mesalazine Sales Value Share by Region (2021-2026) Table 34. Global Oral Mesalazine Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Oral Mesalazine Sales Value Share by Region (2027-2032) Table 36. Global Oral Mesalazine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Oral Mesalazine Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Oral Mesalazine Sales Value Market Share by Country (2021-2026) Table 39. Global Oral Mesalazine Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Oral Mesalazine Sales Value Market Share by Country (2027-2032) Table 41. Teva Pharmaceutical Industries Company Information Table 42. Teva Pharmaceutical Industries Business Overview Table 43. Teva Pharmaceutical Industries Oral Mesalazine Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Teva Pharmaceutical Industries Oral Mesalazine Product Portfolio Table 45. Teva Pharmaceutical Industries Recent Development Table 46. Ferring Global Company Information Table 47. Ferring Global Business Overview Table 48. Ferring Global Oral Mesalazine Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Ferring Global Oral Mesalazine Product Portfolio Table 50. Ferring Global Recent Development Table 51. AbbVie Company Information Table 52. AbbVie Business Overview Table 53. AbbVie Oral Mesalazine Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. AbbVie Oral Mesalazine Product Portfolio Table 55. AbbVie Recent Development Table 56. Tillotts Pharma Company Information Table 57. Tillotts Pharma Business Overview Table 58. Tillotts Pharma Oral Mesalazine Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Tillotts Pharma Oral Mesalazine Product Portfolio Table 60. Tillotts Pharma Recent Development Table 61. Shire Company Information Table 62. Shire Business Overview Table 63. Shire Oral Mesalazine Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Shire Oral Mesalazine Product Portfolio Table 65. Shire Recent Development Table 66. Salix Pharmaceuticals Company Information Table 67. Salix Pharmaceuticals Business Overview Table 68. Salix Pharmaceuticals Oral Mesalazine Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Salix Pharmaceuticals Oral Mesalazine Product Portfolio Table 70. Salix Pharmaceuticals Recent Development Table 71. Nogra Pharma Limited Company Information Table 72. Nogra Pharma Limited Business Overview Table 73. Nogra Pharma Limited Oral Mesalazine Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Nogra Pharma Limited Oral Mesalazine Product Portfolio Table 75. Nogra Pharma Limited Recent Development Table 76. Morningside Healthcare Company Information Table 77. Morningside Healthcare Business Overview Table 78. Morningside Healthcare Oral Mesalazine Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Morningside Healthcare Oral Mesalazine Product Portfolio Table 80. Morningside Healthcare Recent Development Table 81. Dr. Falk Pharma UK Company Information Table 82. Dr. Falk Pharma UK Business Overview Table 83. Dr. Falk Pharma UK Oral Mesalazine Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Dr. Falk Pharma UK Oral Mesalazine Product Portfolio Table 85. Dr. Falk Pharma UK Recent Development Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Oral Mesalazine Product Image Figure 2. Global Oral Mesalazine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Mesalazine Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Mesalazine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Capsules Image Figure 8. Granule Image Figure 9. Tablets Image Figure 10. Global Oral Mesalazine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Oral Mesalazine Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Oral Mesalazine Sales Value Share by Type (2021-2032) Figure 13. Inflammatory Bowel Disease Image Figure 14. Ulcerative Colitis Image Figure 15. Crohn's Disease Image Figure 16. Others Image Figure 17. Global Oral Mesalazine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Oral Mesalazine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Oral Mesalazine Sales Value Share by Application (2021-2032) Figure 20. Global Oral Mesalazine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Oral Mesalazine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Oral Mesalazine Sales Value (2021-2032) & (US$ Million) Figure 23. North America Oral Mesalazine Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Oral Mesalazine Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Oral Mesalazine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Oral Mesalazine Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Oral Mesalazine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Oral Mesalazine Sales Value (2021-2032) & (US$ Million) Figure 29. South America Oral Mesalazine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Oral Mesalazine Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Oral Mesalazine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Oral Mesalazine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Oral Mesalazine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Oral Mesalazine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Capsules
  • Granule
  • Tablets
Applications
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Crohn's Disease
  • Others
Companies covered
  • Teva Pharmaceutical Industries
  • Ferring Global
  • AbbVie
  • Tillotts Pharma
  • Shire
  • Salix Pharmaceuticals
  • Nogra Pharma Limited
  • Morningside Healthcare
  • Dr. Falk Pharma UK

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oral Mesalazine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oral Mesalazine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oral Mesalazine Market Dynamics
  1. 2.1 Oral Mesalazine Industry Trends
  2. 2.2 Oral Mesalazine Industry Drivers
  3. 2.3 Oral Mesalazine Industry Opportunities and Challenges
  4. 2.4 Oral Mesalazine Industry Restraints
3 Oral Mesalazine Market by Company
  1. 3.1 Global Oral Mesalazine Company Revenue Ranking in 2025
  2. 3.2 Global Oral Mesalazine Revenue by Company (2021-2026)
  3. 3.3 Global Oral Mesalazine Company Ranking (2024-2026)
  4. 3.4 Global Oral Mesalazine Company Manufacturing Base and Headquarters
  5. 3.5 Global Oral Mesalazine Company Product Type and Application
  6. 3.6 Global Oral Mesalazine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oral Mesalazine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oral Mesalazine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oral Mesalazine Market by Type
  1. 4.1 Oral Mesalazine Type Introduction
  2. 4.1.1 Capsules
  3. 4.1.2 Granule
  4. 4.1.3 Tablets
  5. 4.2 Global Oral Mesalazine Sales Value by Type
  6. 4.2.1 Global Oral Mesalazine Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Oral Mesalazine Sales Value by Type (2021-2032)
  8. 4.2.3 Global Oral Mesalazine Sales Value Share by Type (2021-2032)
5 Oral Mesalazine Market by Application
  1. 5.1 Oral Mesalazine Application Introduction
  2. 5.1.1 Inflammatory Bowel Disease
  3. 5.1.2 Ulcerative Colitis
  4. 5.1.3 Crohn's Disease
  5. 5.1.4 Others
  6. 5.2 Global Oral Mesalazine Sales Value by Application
  7. 5.2.1 Global Oral Mesalazine Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Oral Mesalazine Sales Value by Application (2021-2032)
  9. 5.2.3 Global Oral Mesalazine Sales Value Share by Application (2021-2032)
6 Oral Mesalazine Regional Value Analysis
  1. 6.1 Global Oral Mesalazine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Mesalazine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oral Mesalazine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oral Mesalazine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oral Mesalazine Sales Value (2021-2032)
  7. 6.3.2 North America Oral Mesalazine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oral Mesalazine Sales Value (2021-2032)
  10. 6.4.2 Europe Oral Mesalazine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oral Mesalazine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oral Mesalazine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oral Mesalazine Sales Value (2021-2032)
  16. 6.6.2 South America Oral Mesalazine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oral Mesalazine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oral Mesalazine Sales Value Share by Country, 2025 VS 2032
7 Oral Mesalazine Country-level Value Analysis
  1. 7.1 Global Oral Mesalazine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oral Mesalazine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oral Mesalazine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oral Mesalazine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oral Mesalazine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oral Mesalazine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oral Mesalazine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oral Mesalazine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oral Mesalazine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oral Mesalazine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oral Mesalazine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oral Mesalazine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oral Mesalazine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oral Mesalazine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oral Mesalazine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oral Mesalazine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oral Mesalazine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oral Mesalazine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oral Mesalazine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oral Mesalazine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oral Mesalazine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oral Mesalazine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oral Mesalazine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oral Mesalazine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oral Mesalazine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oral Mesalazine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oral Mesalazine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oral Mesalazine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oral Mesalazine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oral Mesalazine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oral Mesalazine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oral Mesalazine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oral Mesalazine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oral Mesalazine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries
  2. 8.1.1 Teva Pharmaceutical Industries Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Oral Mesalazine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Oral Mesalazine Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 8.2 Ferring Global
  8. 8.2.1 Ferring Global Company Information
  9. 8.2.2 Ferring Global Business Overview
  10. 8.2.3 Ferring Global Oral Mesalazine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ferring Global Oral Mesalazine Product Portfolio
  12. 8.2.5 Ferring Global Recent Developments
  13. 8.3 AbbVie
  14. 8.3.1 AbbVie Company Information
  15. 8.3.2 AbbVie Business Overview
  16. 8.3.3 AbbVie Oral Mesalazine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Oral Mesalazine Product Portfolio
  18. 8.3.5 AbbVie Recent Developments
  19. 8.4 Tillotts Pharma
  20. 8.4.1 Tillotts Pharma Company Information
  21. 8.4.2 Tillotts Pharma Business Overview
  22. 8.4.3 Tillotts Pharma Oral Mesalazine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tillotts Pharma Oral Mesalazine Product Portfolio
  24. 8.4.5 Tillotts Pharma Recent Developments
  25. 8.5 Shire
  26. 8.5.1 Shire Company Information
  27. 8.5.2 Shire Business Overview
  28. 8.5.3 Shire Oral Mesalazine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shire Oral Mesalazine Product Portfolio
  30. 8.5.5 Shire Recent Developments
  31. 8.6 Salix Pharmaceuticals
  32. 8.6.1 Salix Pharmaceuticals Company Information
  33. 8.6.2 Salix Pharmaceuticals Business Overview
  34. 8.6.3 Salix Pharmaceuticals Oral Mesalazine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Salix Pharmaceuticals Oral Mesalazine Product Portfolio
  36. 8.6.5 Salix Pharmaceuticals Recent Developments
  37. 8.7 Nogra Pharma Limited
  38. 8.7.1 Nogra Pharma Limited Company Information
  39. 8.7.2 Nogra Pharma Limited Business Overview
  40. 8.7.3 Nogra Pharma Limited Oral Mesalazine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Nogra Pharma Limited Oral Mesalazine Product Portfolio
  42. 8.7.5 Nogra Pharma Limited Recent Developments
  43. 8.8 Morningside Healthcare
  44. 8.8.1 Morningside Healthcare Company Information
  45. 8.8.2 Morningside Healthcare Business Overview
  46. 8.8.3 Morningside Healthcare Oral Mesalazine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Morningside Healthcare Oral Mesalazine Product Portfolio
  48. 8.8.5 Morningside Healthcare Recent Developments
  49. 8.9 Dr. Falk Pharma UK
  50. 8.9.1 Dr. Falk Pharma UK Company Information
  51. 8.9.2 Dr. Falk Pharma UK Business Overview
  52. 8.9.3 Dr. Falk Pharma UK Oral Mesalazine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Dr. Falk Pharma UK Oral Mesalazine Product Portfolio
  54. 8.9.5 Dr. Falk Pharma UK Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst